deCode Genetics ehf
Records under this name other than the patents deCode Genetics ehf holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,795,963 | Genetic Markers for Risk Management of Atrial Fibrillation and Stroke Lapsed on the fee record Ended Aug 5, 2026 · High confidence | Lapsed on the fee record | Ended Aug 5, 2026 | High confidence |
| US 8,796,182 | Genetic Markers Associated with Risk of Diabetes Mellitus Lapsed on the fee record Ended Aug 5, 2026 · High confidence | Lapsed on the fee record | Ended Aug 5, 2026 | High confidence |
| US 7,152,073 | Method and system for defining sets by querying relational data using a set definition language Term ended Term ended Jul 10, 2024 · From the USPTO record | Term ended | Term ended Jul 10, 2024 | From the USPTO record |
| US 7,404,079 | Automatic identity protection system with remote third party monitoring Term ended Term ended Sep 10, 2023 · From the USPTO record | Term ended | Term ended Sep 10, 2023 | From the USPTO record |
| US 7,495,147 | NEUREGULIN-1 Transgenic Mouse and Methods of Use Lapsed on the fee record Ended Feb 24, 2021 · Medium confidence | Lapsed on the fee record | Ended Feb 24, 2021 | Medium confidence |
| US 8,367,333 | Genetic variants as markers for use in diagnosis, prognosis and treatment of eosinophilia, asthma, and myocardial infarction Lapsed on the fee record Ended Feb 5, 2021 · From the USPTO record | Lapsed on the fee record | Ended Feb 5, 2021 | From the USPTO record |
| US 6,818,425 | RNA Ligase of Bacteriophage RM 378 Formerly held Term ended Term ended Jun 1, 2020 · Medium confidence | Term ended | Term ended Jun 1, 2020 | Medium confidence |
| US 8,951,735 | Genetic variants for breast cancer risk assessment Lapsed on the fee record Ended Feb 10, 2019 · From the USPTO record | Lapsed on the fee record | Ended Feb 10, 2019 | From the USPTO record |
| US 8,883,833 | Substituted benzoazole PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders Lapsed on the fee record Ended Nov 11, 2018 · From the USPTO record | Lapsed on the fee record | Ended Nov 11, 2018 | From the USPTO record |
| US 8,877,816 | 4-(or 5-) substituted catechol derivatives Lapsed on the fee record Ended Nov 4, 2018 · From the USPTO record | Lapsed on the fee record | Ended Nov 4, 2018 | From the USPTO record |